Guggenheim Capital LLC reduced its position in shares of Haemonetics Co. (NYSE:HAE – Get Rating) by 1.1% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 12,078 shares of the medical instruments supplier’s stock after selling 132 shares during the quarter. Guggenheim Capital LLC’s holdings in Haemonetics were worth $894,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also bought and sold shares of the company. Lazard Asset Management LLC bought a new stake in Haemonetics during the 3rd quarter valued at about $3,253,000. Ergoteles LLC bought a new stake in Haemonetics during the 3rd quarter valued at about $742,000. Centiva Capital LP increased its stake in Haemonetics by 31.8% during the 3rd quarter. Centiva Capital LP now owns 6,589 shares of the medical instruments supplier’s stock valued at $488,000 after purchasing an additional 1,589 shares in the last quarter. Nuveen Asset Management LLC boosted its holdings in shares of Haemonetics by 3.4% during the 3rd quarter. Nuveen Asset Management LLC now owns 191,356 shares of the medical instruments supplier’s stock valued at $14,166,000 after acquiring an additional 6,350 shares during the last quarter. Finally, FORA Capital LLC purchased a new stake in shares of Haemonetics during the 3rd quarter valued at about $353,000.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on HAE shares. Morgan Stanley raised their price target on shares of Haemonetics from $84.00 to $88.00 and gave the company an “equal weight” rating in a report on Wednesday, February 8th. Citigroup raised their price target on shares of Haemonetics from $92.00 to $95.00 and gave the company a “neutral” rating in a report on Wednesday, February 8th. Raymond James raised their price target on shares of Haemonetics from $88.00 to $100.00 and gave the company an “outperform” rating in a report on Tuesday, November 8th. Mizuho raised their price target on shares of Haemonetics from $110.00 to $115.00 and gave the company a “buy” rating in a report on Wednesday, February 8th. Finally, JMP Securities raised their price objective on shares of Haemonetics from $90.00 to $105.00 and gave the stock a “market outperform” rating in a report on Tuesday, November 8th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, Haemonetics currently has an average rating of “Moderate Buy” and an average target price of $101.00.
Haemonetics Price Performance
Haemonetics (NYSE:HAE – Get Rating) last issued its quarterly earnings results on Tuesday, February 7th. The medical instruments supplier reported $0.85 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.06. Haemonetics had a net margin of 8.48% and a return on equity of 19.84%. The business had revenue of $305.30 million for the quarter, compared to the consensus estimate of $300.47 million. During the same quarter in the previous year, the firm earned $0.84 earnings per share. The company’s revenue for the quarter was up 17.5% on a year-over-year basis. Research analysts expect that Haemonetics Co. will post 2.94 EPS for the current fiscal year.
Insider Buying and Selling at Haemonetics
In other news, EVP Josep Llorens sold 2,391 shares of Haemonetics stock in a transaction that occurred on Monday, January 23rd. The shares were sold at an average price of $90.00, for a total transaction of $215,190.00. Following the sale, the executive vice president now owns 17,234 shares in the company, valued at $1,551,060. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 1.65% of the company’s stock.
Haemonetics Company Profile
Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems.
- Get a free copy of the StockNews.com research report on Haemonetics (HAE)
- Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
- Market Gets “Powelled”: S&P 500 Confirms Resistance
- Ulta Insiders Hold Tight: Sell-Siders Buy
- Rivian Plummets, But Is This 2023’s Greatest Buying Opportunity?
- Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE – Get Rating).
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.